**In Silico Assigned Resistance Genes Confer Bifidobacterium with Partial Resistance to Aminoglycosides but Not to B-Lactams**

Fiona Fouhy1,2, Mary O’Connell Motherway2,3, Gerald F. Fitzgerald2,3, R. Paul Ross1,3, Catherine Stanton1,3, Douwe van Sinderen2,3, Paul D. Cotter1,3*

1 Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland, 2 Microbiology Department, University College Cork, Cork, Ireland, 3 Alimentary Pharmabiotic Centre, Cork, Ireland

**Abstract**

Bifidobacteria have received significant attention due to their contribution to human gut health and the use of specific strains as probiotics. It is thus not surprising that there has also been significant interest with respect to their antibiotic resistance profile. Numerous culture-based studies have demonstrated that bifidobacteria are resistant to the majority of aminoglycosides, but are sensitive to β-lactams. However, limited research exists with respect to the genetic basis for the resistance of bifidobacteria to aminoglycosides. Here we performed an in-depth *in silico* analysis of putative *Bifidobacterium*-encoded aminoglycoside resistance proteins and β-lactamases and assess the contribution of these proteins to antibiotic resistance. The *in silico*-based screen detected putative aminoglycoside and β-lactam resistance proteins across the *Bifidobacterium* genus. Laboratory-based investigations of a number of representative bifidobacteria strains confirmed that despite containing putative β-lactamases, these strains were sensitive to β-lactams. In contrast, all strains were resistant to the aminoglycosides tested. To assess the contribution of genes encoding putative aminoglycoside resistance proteins in *Bifidobacterium* sp. two genes, namely *Bbr_0651* and *Bbr_1586*, were targeted for insertional inactivation in *B. breve* UCC2003. As compared to the wild-type, the UCC2003 insertion mutant strains exhibited decreased resistance to gentamicin, kanamycin and streptomycin. This study highlights the associated risks of relying on the *in silico* assignment of gene function. Although several putative β-lactam resistance proteins are located in bifidobacteria, their presence does not coincide with resistance to these antibiotics. In contrast however, this approach has resulted in the identification of two loci that contribute to the aminoglycoside resistance of *B. breve* UCC2003 and, potentially, many other bifidobacteria.

**Introduction**

Following the discovery of penicillin by Alexander Fleming [1], exponential antibiotic discovery and development occurred which revolutionized medicine. However, during this same period, target bacteria developed sophisticated mechanisms of resistance against many of the most commonly prescribed antibiotics [2]. It is thus not surprising that considerable efforts have been and are still being made to investigate the genetic mechanisms involved in the transfer, acquisition and expression of antibiotic resistance genes, in order to curtail or prevent the further development of resistance [3,4].

The mechanisms underlying resistance to aminoglycosides and to β-lactams are among those that have been the focus of particular attention. Briefly, aminoglycosides are a family of broad spectrum antibiotics that were first reported in 1944 [5], whose bactericidal activity results from their binding to the 30S subunit of the prokaryotic ribosome and the subsequent impairment of protein synthesis [5,6]. Aminoglycoside resistance can be mediated through reduced aminoglycoside uptake [7], or through enzymatic modification of the
aminoglycoside through the activity of the N-acetyltransferases (AAC), O-nucleotidytransferases (ANT) or O-phosphotransferases (APH). Aminoglycoside resistance genes have been classified based on the enzymatic modification mechanism used by the resultant protein and the chemical position at which the aminoglycoside is modified [8].

β-lactam antibiotics are a class of broad spectrum antibiotics which include the penicillins and cephalosporins [9]. β-lactams inhibit bacteria by their interference with normal cell wall synthesis, via disruption of the final cross-linking stage of cell wall peptidoglycan formation, resulting in a significantly weakened cell wall polymer, ultimately leading to bacterial cell death [10-12]. β-lactam resistance can arise through mutation of target penicillin binding proteins (PBPs; [13,14]), as well as through the production of β-lactamases [15], which catalyze the hydrolysis of the eponymous β-lactam rings present in β-lactam antibiotics, rendering the antibiotic inactive. β-lactamase classification has undergone significant rounds of change from the initial Ambler classification proposed in 1973 [16] and the classification schemes of Bush and colleagues [17-20].

The antibiotic resistance genes of pathogenic bacteria have been the focus of greatest attention. Similarly, antibiotic sensitivity is regarded as a desirable trait among candidate probiotic strains for the feed [21] and human [22,23] markets. Such a phenotype ensures that their consumption does not further increase the risk of antibiotic resistance gene dissemination, especially in situations where such genes are located on mobile genetic elements. Gut-associated bifidobacteria are generally viewed as beneficial microbes and many strains have been attributed with health-promoting characteristics [24-27]. Thus, it is not surprising that many bifidobacteria are used, or have been studied with a view to their potential use, as probiotics in functional foods [28]. As a consequence, there has been considerable interest in determining if certain bifidobacteria possess antibiotic resistance genes [29-32]. These studies established that the tested bifidobacteria strains are generally resistant to aminoglycoside antibiotics [33], but are sensitive to β-lactams [29,31,34,35]. In a previous study, we found that combined ampicillin and gentamycin treatment in infants, caused a significant decrease in the proportion of bifidobacteria present 4 weeks after antibiotic administration ceased, while also significantly altering the bifidobacteria species present [36]. We were therefore interested in investigating differences in the distribution of genes encoding β-lactam or aminoglycoside resistance proteins among members of the Bifidobacterium genus.

To date little is known about the genetic mechanisms that underlie aminoglycoside resistance in bifidobacteria. Despite the existence of some specific studies [32,37,38], the presence of antibiotic resistance genes has been more frequently inferred through the annotation of DNA sequences and the identification of genes bearing some homology to genes previously assigned as being potential resistance determinants. Given the risks associated with relying exclusively on rapid in silico assignments, here we present an in-depth bioinformatic analysis of putative β-lactam and aminoglycoside resistance proteins that are Bifidobacterium-encoded. We have investigated if a correlation exists between these proteins and antibiotic resistance and, in the case of aminoglycoside resistance, have demonstrated the contribution of the assigned resistance genes to this phenotype.

**Materials and Methods**

**NCBI database search for Bifidobacterium-associated β-lactam and aminoglycoside resistance proteins**

Using the NCBI protein database, a search for putative β-lactamases and aminoglycoside resistance proteins associated with bifidobacteria was completed using the terms ‘beta-lactamase’ and ‘Bifidobacterium’ (searched on 28/8/12) and ‘aminoglycoside’ and ‘Bifidobacterium’ (search completed on 29/8/12). This approach was taken so that all such proteins, regardless of the basis upon which they were assigned, would be revealed. Following the removal of duplicates and sequences that did not originate from Bifidobacterium, all remaining sequences were used as drivers for subsequent rounds of BLAST investigations. All subsequent distinct sequences detected were employed for additional BLAST-based investigations until a finalized list was achieved. Additionally, further BLAST-based investigations using known β-lactamase and aminoglycoside resistance proteins as drivers were completed to ensure no additional sequences were overlooked.

**Classification of β-lactamases and aminoglycoside resistance protein sequences from bifidobacteria**

Putative Bifidobacterium-associated β-lactamase and aminoglycoside resistance proteins were subjected to in silico analysis with a view to classifying them using the Ambler method for β-lactamases [17], or assigning them into one of the 3 main enzyme modification groups associated with aminoglycoside resistance [8]. To this end, the putative Bifidobacterium-associated resistance determinants were aligned (MegAlign Clustal W, LaserGene) against representative sequences from each class (A-D for the β-lactamases) and from each of the 3 enzyme groups (AAC, APH and ANT for the aminoglycosides) [19,20] (Table 1).

**Laboratory based assessments of antibiotic resistance**

The antibiotic susceptibility of bifidobacteria strains was investigated in a number of different ways. Disc diffusion assays were carried out according to the British Society for Antimicrobial Chemotherapy (BSAC) guidelines [39-41]. Briefly the bifidobacteria strains were cultured overnight anaerobically and delivered onto Iso-Sensitest agar plates (Oxoid, Fisher Scientific, Dublin, Ireland) using a swab in three directions. Antimicrobial discs containing ampicillin (25 µg), penicillin (10 µg) (VWR International, Dublin, Ireland), neomycin (30 µg), gentamycin (200 µg), kanamycin (30 µg) and streptomycin (25 µg) (Fisher Scientific, Dublin, Ireland) were dispensed manually onto the agar plates. Following anaerobic incubation at 37°C for 48 hours, the diameters of the zones of inhibition (mm) were measured. All tests were carried out in triplicate.
Minimum inhibitory concentration tests (MICs) using 4 aminoglycosides i.e. neomycin, gentamycin, streptomycin and kanamycin (Sigma Aldrich, Dublin, Ireland) were performed as per the micro-dilution method, as described in detail by others [42]. Briefly, bifidobacteria were grown overnight anaerobically at 37°C in MRS broth supplemented with 0.05% cysteine (Sigma Aldrich, Wexford, Ireland). Cultures were adjusted to an OD600 of 0.1 (=1 x 10^8 cfu/ml) in fresh MRS broth (media pH 6.8). Stock solutions of each of the aminoglycoside antibiotics were prepared in sterile distilled water and a 2-fold dilution series was performed. An inoculum of 100 µl of culture was added to each well of the 96 well plate (resulting in a final concentration of ≈ 5 x 10^4 cfu/ml) (Sarstedt, Wexford, Ireland). Cultures were incubated aerobically at 37°C.

Table 1. Representative sequences used as drivers for Blast based investigations into *Bifidobacterium*-associated aminoglycoside resistant proteins and β-lactamases.

| Aminoglycoside resistance gene classification groups | Representative sequences | β-lactamase gene classes | Representative gene name | Representative gene accession number |
|---------------------------------------------------|---------------------------|--------------------------|--------------------------|-------------------------------------|
| APH                                               | M20305                    | Class A                  | TEM1                     | YP_209323.1                         |
|                                                   | M29953                    | Class B                  | IMP-1                    | YP_005980003.1                      |
|                                                   | X07753                    | Class C                  | Sph1                     | YP_005188946.1                      |
| APH (6')                                          | X05648                    | Class A                  | Bla KPC                  | YP_003754012.1                      |
|                                                   | X013072                   | Class B                  | IMP-1                    | YP_005980003.1                      |
|                                                   | X01385                    | Class C                  | AMP C                    | YP_006262.1                         |
| AAC 3                                             | M55426                    | Class B                  | IMP-1                    | YP_005980003.1                      |
| AAC-la & lb                                       | M06157                    | Class C                  | Sph1                     | YP_005188946.1                      |
| AAC 6' & 6'lc                                     | M94068                    | Class C                  | Sph1                     | YP_005188946.1                      |
| ANT                                               | X02340                    | Class B                  | Bla KPC                  | YP_003754012.1                      |
|                                                  | X04555                    | Class C                  | AMP C                    | YP_006262.1                         |
| Class C                                           | OXA-1                     | Class D                  | OXA-10                   | YP_001715358.1                      |
| Class D                                           | OXA-23                    | Class D                  | OXA-23                   | YP_002317955.1                      |

Minimum inhibitory concentration tests (MICs) using 4 aminoglycosides i.e. neomycin, gentamycin, streptomycin and kanamycin (Sigma Aldrich, Dublin, Ireland) were performed as per the micro-dilution method, as described in detail by others [42]. Briefly, bifidobacteria were grown overnight anaerobically at 37°C in MRS broth supplemented with 0.05% cysteine (Sigma Aldrich, Wexford, Ireland). Cultures were adjusted to an OD600 of 0.1 (=1 x 10^8 cfu/ml) in fresh MRS broth (media pH 6.8). Stock solutions of each of the aminoglycoside antibiotics were prepared in sterile distilled water and a 2-fold dilution series was performed. An inoculum of 100 µl of culture was added to each well of the 96 well plate (resulting in a final concentration of ≈ 5 x 10^4 cfu/ml) (Sarstedt, Wexford, Ireland). Cultures were incubated aerobically at 37°C.

Disruption of the Bbr_0651 and Bbr_1586 genes from *B. breve UCC2003*

Site specific homologous recombination was used to disrupt 2 genes present in *B. breve UCC2003*, namely Bbr_0651 and Bbr_1586, using protocols similar to those previously described [45,46]. Briefly, internal fragments of Bbr_0651 and Bbr_1586, were amplified by PCR using specifically designed primers (MWG Eurofins, Germany) (Table S1), resulting in 500bp and 400bp products respectively. These fragments were cloned into the pORI19 vector and a tetracycline resistance marker (tetW gene) from the pAM5 vector [47] was subcloned to generate the plasmids pORI19-tet-0651 and pORI19-tet-1586 (Table 2). The correct sequence of each cloned insert was verified by sequencing (Source BioScience, Dublin, Ireland).

Being derivatives of pORI19 these plasmids cannot replicate in *B. breve UCC2003*, due to a lack of a functional replication protein [48], and instead are utilised with a view to integrating into and disrupting target genes. To facilitate methylation, the pORI19 plasmids were introduced via electroporation into EC101 *E. coli* cells containing pNZ-M.BbrII-M.BbrIII. The resulting methylated pORI19-tet-0651 and pORI19-tet-1586 constructs were electroporated into *B. breve UCC2003*. Transformants were selected based on presence of tetracycline resistance. Transformants were expected to carry Bbr_0651 or Bbr_1586 gene disruptions, respectively. To verify the suspected chromosomal integration of these pORI19 constructs, colony PCRs were performed on a selection of tetracycline resistant transformants, using a forward primer
upstream of the integration region and a reverse primer based on pORI19 (Table S1).

**Complementation studies**

DNA fragments containing the gene Bbr_1586 and its native promoter region were generated by PCR amplification from B. breve UCC2003 chromosomal DNA, using Pfu Ultra II Hotstart Mastermix (Agilent Technologies, Cork, Ireland) and sequence specific primers (Table S1). The amplicons and the pBC1.2 plasmid were digested with HincIII and XbaI (Roche Diagnostics, Sussex, UK) and subsequently ligated using T4 DNA ligase (Roche Diagnostics, Sussex, UK). This resulted in the complementation plasmid pBC1.2-Bbr_1586 (Table 2). The dialysed ligations were electroporated into E. coli XL1-blue and the resulting plasmids verified by PCR and restriction digest analysis. Finally, the plasmid pBC1.2-Bbr_1586 was electroporated into competent B. breve UCC2003-1586-tet cells. Transformants from the complemented strain were selected and the presence of the construct confirmed.

**Studies of wild-type B. breve UCC2003 with additional copies of aminoglycoside resistance genes**

Studies were also completed to investigate if the addition of extra plasmid-encoded copies of the putative aminoglycoside resistance genes Bbr_0651, Bbr_0651+0650 or Bbr_1586 would result in enhanced resistance of the wild-type B. breve UCC2003. Competent B. breve UCC2003 cells were prepared and transformed with the constructs pBC1.2-0651, pBC1.2-0651+0650 or pBC1.2-1586. Transformants were selected and the presence of the plasmid inserts was confirmed.
Heterologous expression of putative aminoglycoside resistance genes in *E. coli*

Plasmid-encoded copies of the entire putative aminoglycoside resistance genes Bbr_0651, Bbr_0651+0650 and Bbr_1586, along with their native promoters were transformed via electroporation into competent *E. coli* XL1-blue. Following confirmation of the presence of the correct plasmid insert in the transformants, MIC assays were completed, using the protocol outlined above.

Results

Putative β-lactamases associated with *Bifidobacterium* species

In order to identify *Bifidobacterium*-associated proteins which have been annotated, or possibly mis-annotated, as β-lactamases, the NCBI protein database was screened for *Bifidobacterium*-associated proteins which had been annotated as β-lactamases or which had been noted to contain β-lactamase associated motifs (searched on 28/8/12). The proteins identified were in turn employed as drivers for BLAST analysis (of non-redundant proteins), to identify and assess the distribution of related *Bifidobacterium*-associated proteins. Subsequent rounds of BLAST analysis, employing the related, yet distinct, protein sequences as drivers, ultimately resulted in saturation. To ensure that other potential β-lactamases were not overlooked, further BLAST-based investigations, using known β-lactamase proteins as drivers, were also carried out to screen all publically available *Bifidobacterium* genomes.

The resultant proteins fell into a number of different categories (Table 3). The most common protein was that annotated variably as a metallo-beta-lactamase family protein, a metal-dependent hydrolase or ribonuclease J such as HMPREF0168_0178 from *B. dentium* ATCC 27679. This protein is conserved, at high (>90%) percentage identity, across almost all publically available *Bifidobacterium* genomes and is a member of the protein family 07521 (Pfam07521; RNA-metabolising metallo-beta-lactamases). A considerable number of other proteins are linked by virtue of containing domains typical of Pfam13354 (a β-lactamase enzyme family of proteins). These proteins are not highly conserved, with distinct subgroups such as those represented by HMPREF0168_1872 from *B. dentium* ATCC 27679, BBB_1387 from *B. bifidum* BGN4, BBB_1559 from *B. bifidum* BGN4 and Bbr_0236 from *B. breve* UCC2003, respectively, being apparent. Other unique members of Pfam13354 are BIFADO_0224 (*B. adolescentis* L2-32), BLJ0695 (*B. longum* subsp. *longum* JDM 301) and BAD_1308 (*B. adolescentis* ATCC 15703). *B. dentium* genomes also share a conserved protein, representative of Pfam00144 (a β-lactamase family protein), such as HMPREF0168_1378 from *B. dentium* ATCC 27679. *B. catenulatum* DSM 16992 (BIFCAT_01331) and *B. pseudocatenulatum* DSM 20438 (BIFPSEUDO_02501) also contained proteins from this family (PF00144) which were highly conserved (>90% identity). However, these were distinct from other PF00144 family proteins associated with *B. dentium* ATCC 27679. The remaining protein of potential relevance is Blon_2358 from *B. longum* subsp. *infantis* ATCC 15697. This protein has been assigned as a β-lactamase but, unlike the other proteins referred to above, its closest homologues are not other *Bifidobacterium*-associated proteins but, rather, are proteins that have been found in the genomes of various clostridia, enterococci and lactobacilli. In addition to containing domains corresponding to Pfam07251, this protein is also representative of Pfam12706, i.e. the lactamase_B_2 family of proteins.

Putative aminoglycoside resistance proteins associated with *Bifidobacterium* species

An identical approach to that taken for the β-lactamases, was taken to identify *Bifidobacterium*-associated proteins which had been annotated, or potentially mis-annotated, as aminoglycoside resistance proteins. A search of the NCBI protein database using the terms ‘aminoglycoside’ and ‘*Bifidobacterium*’ was completed (search completed on 29/8/12). The analysis revealed that putative aminoglycoside resistance proteins are widely distributed across the *Bifidobacterium* genus, and are particularly common among strains of *B. longum* (Table 4). Furthermore, it appears that all putative *Bifidobacterium*-associated aminoglycoside resistance proteins can be broadly classified into 3 groups i.e. those containing proteins of the family Pfam01636 (phosphotransferase enzyme family), proteins containing a protein kinase family domain, c109925, or those which appear to contain both. While some of these proteins appeared to be highly conserved within or across bifidobacteria strains and species, some proteins appear to be much more distantly related. The results indicated that only one putative protein was solely associated with the protein family Pfam01636, namely BBMN_137 from *B. longum* BBMN68. In a number of other instances proteins which were members of Pfam01636 and which also contained the c109925 domain, were noted. In some cases these proteins were annotated as aminoglycoside phosphotransferases, e.g. BIF_01665 (*B. animalis* subsp. *lactis* Bb12), while in other cases they were annotated as desulfatases, e.g. BL_1642 (*B. longum* NCC 2705), or homoserine kinases, e.g. BBMN_1674 (*B. longum* BBMN8). In addition, *B. bifidum* BGN4 BB_00978 and *B. bifidum* S17 BB_0997 also exhibit characteristics of Pfam01636 and possess a protein kinase domain, but have been annotated as an N-acetyl hexosamine kinase and a mucin desulfatase, respectively. In this instance, laboratory-based investigations have previously established that this gene does indeed encode N-acetyl hexosamine kinase [49]. Some sequences which were annotated as being from Pfam01636 and also contained a protein kinase family domain were highly conserved (with >90% percentage identity) e.g. BLD_1766 (*B. longum* DJ010A) and BLIG_01601 from *B. longum* subsp. *infantis* CCUG 52486. However, in other instances, these proteins were more distantly related e.g. BBIF_0997 (*B. bifidum* S17) and Bbr_1586 (*B. breve* UCC2003).

Proteins containing a protein kinase family domain, c109925, only and also annotated as aminoglycoside phosphotransferase or hypothetical proteins are also widely distributed across *Bifidobacterium* species. Some of these, such as BLD_0109 (*B. longum* DJ010A), Blon_0773 (*B.
Table 3. *Bifidobacterium* derived β-lactamase protein sequences.

| Bifidobacterium strain | Accession number* | Gene name | Assigned as | Pfam |
|------------------------|------------------|-----------|-------------|------|
| *B. dentium* ATCC 27679 | ZP_07457312.1<sup>a</sup> | HMPREF0168_1872 | Conserved hypothetical protein | PF13354 |
| | ZP_07456818.1<sup>b</sup> | HMPREF0168_1378 | β-lactamase | PF00144 |
| | ZP_07456519.1<sup>c</sup> | HMPREF0168_0178 | Hypothetical protein | |
| *B. dentium* Bd1 | YP_003359579.1<sup>a</sup> | BDP_0063 | Hypothetical protein | PF13354 |
| | YP_003360049.1<sup>b</sup> | BDP_0556 | Hypothetical protein | PF00144 |
| | YP_003361117.1<sup>d</sup> | BDP_1754 | Hypothetical protein | |
| *B. dentium* ATCC 27688 | ZP_02917480.1<sup>a</sup> | BIFDEN_00760 | Hypothetical protein | PF13354 |
| | ZP_02916953.1<sup>b</sup> | BIFDEN_00213 | Hypothetical protein | PF00144 |
| | ZP_02918099.1<sup>d</sup> | BIFDEN_01398 | Hypothetical protein | |
| *B. gallicum* DSM 20093 | ZP_05965566.1<sup>e</sup> | BIFGAL_03078 | Metallo-beta-lactamase family protein | |
| *B. adolescentis* L2-32 | ZP_02027816.1 | BIFADO_0224 | Hypothetical protein | PF13354 |
| | ZP_02029327.1<sup>d</sup> | BIFADO_01784 | Hypothetical protein | |
| *B. animalis* subsp. lactis Bb12 | YP_005575727.1<sup>e</sup> | BIF_01983 | Hydrolase | |
| *B. animalis* subsp. lactis AD011 | YP_002469408.1<sup>d</sup> | BANAN_06475 | Hypothetical protein | |
| *B. animalis* subsp. animalis ATCC 25527 | YP_005575727.1<sup>d</sup> | BANAN_06475 | Hypothetical protein | |
| *B. animalis* subsp. lactis AD011 | YP_002469408.1<sup>f</sup> | BIFDEN_00760 | Hypothetical protein | |
| *B. bifidum* BGN4 | YP_006394858.1<sup>f</sup> | BBB_1387 | Penicillin binding protein | PF13354 |
| | YP_006395029.1<sup>f</sup> | BBB_1559 | β-lactamase | PF13354 |
| | YP_006393888.1<sup>e</sup> | BBB_0414 | Ribonuclease J | |
| *B. bifidum* NCIMB 41171 | ZP_07803038.1<sup>g</sup> | BBNG_01520 | Conserved hypothetical protein | |
| | ZP_07801866.1<sup>g</sup> | BBNG_00347 | Conserved hypothetical protein | |
| *B. bifidum* PRL 2010 | YP_003971645.1<sup>f</sup> | BBPR_0437 | Metal-dependent hydrolase | |
| *B. breve* UCC2003 | ABE94495.1<sup>e</sup> | Bbr_0236 | Conserved hypothetical protein with β-lactamase motif | PF13354 |
| *B. breve* ACS 071 VSch8b | YP_005582166.1<sup>e</sup> | HMPREF9228_0250 | Hypothetical protein | PF13354 |
| | YP_005583195.1<sup>f</sup> | HMPREF9228_1387 | Hypothetical protein | |
| *B. breve* DSM 20213 | ZP_06595304.1<sup>e</sup> | BIFBRE_03112 | Putative β-lactamase | PF13354 |
| | ZP_06595596.1<sup>f</sup> | BIFBRE_03411 | Metallo-beta-lactamase family protein | |
| *B. breve* CECT 7263 | EHS86772.1<sup>e</sup> | CECT7263_10968 | Putative β-lactamase | PF13354 |
| | EHS85412.1<sup>e</sup> | CECT7263_11981 | Metallo-beta-lactamase family protein | |
| *B. catenulatum* DSM 16992 | ZP_03324536.1<sup>e</sup> | BIFCAT_01331 | Hypothetical protein | PF00144 |
| | ZP_03324350.1<sup>e</sup> | BIFCAT_01138 | Hypothetical protein | |
| *B. bifidum* S17 | YP_003939138.1<sup>f</sup> | BBIF_1359 | β-lactamase | PF13354 |
Table 3 (continued).

| Bifidobacterium strain | Accession number/Genename | Assigned as | Pfam |
|------------------------|---------------------------|-------------|------|
| B. longum DSM 20438    | ZP_03741949.10            | Hypothetical protein | PF00144 |
| B. longum NCC2705      | NP696361.10               | BL_1192 Hypothetical protein | PF07521 |
| B. longum DSM 20098    | ZP_03976420.10            | Metal dependent hydrolase | PF07521 |
| B. longum DSM 20438    | YP_004000557.10           | BMN68_955 Hydrolase | PF07521 |
| B. longum CECT7263_10981 | ZP_03742801.10           | Hypothetical protein | PF07521 |

1 Same superscript indicates proteins share >90% sequence percentage identity

doi: 10.1371/journal.pone.0082653.t003

longum subsp. infantis ATCC 15697 (B. longum subsp. longum JDM301), are highly conserved while others, such as BLJ_1379 (B. longum subsp. longum JDM301) and BIFANG_02451 (B. angulatum DSM 20098), are more distantly related. Finally, 4 proteins (Bbr_0651, BIFBRE_03589, CECT7263_10981 and HMPREF9228_1217) were annotated as containing both a protein kinase family domain from c109925, while also containing a protein from the Pfam07462 (merozoite surface proteins). These 4 proteins were very highly conserved within the B. breve species sharing >99% percentage identity, while being more distantly related to proteins from other Bifidobacterium species, e.g. BIFANG_02451 from B. angulatum DSM 20098, which did not contain any protein of the Pfam07462.

We also investigated if the β-lactamases and aminoglycoside resistant protein sequences detected in bifidobacteria, could be classified according to the Ambler classes A-D for β-lactamases and acetylation, adenylation and phosphorylation enzymes for aminoglycosides. However, due to insufficient similarity with the sequences of known β-lactamases and aminoglycoside resistance proteins from other genera, such classifications were not possible.

Laboratory-based assessment of the antibiotic resistance of representative bifidobacterial strains

Laboratory tests were conducted with a number of representative Bifidobacterium species to determine if the presence of putative antibiotic resistance proteins corresponded to antibiotic resistance. The specific strains used had been determined, on the basis of the in silico screen, to contain putative β-lactam and/or aminoglycoside resistance genes. The use of different species and strains enabled us to determine if the results were genus, species or strain specific. The strains tested were B. breve UCC2003, B. breve DSM 20213, B. gallicum DSM 20093, B. animalis subsp. lactis Bb12, B. angulatum DSM 20098 and B. pseudocatenulatum DSM 20438 (Table 2). Disc diffusion assays were performed using both aminoglycoside [kanamycin (30µg), gentamycin (200 µg), streptomycin (25 µg) and neomycin (30 µg)] and β-lactam antibiotic discs [ampicillin (25 µg) and penicillin (10 µg)]. Following anaerobic incubation at 37°C for 48 hours, zones of inhibition were measured (Table 5). All tests were performed in triplicate. The results indicated that all strains tested were highly sensitive to the β-lactam antibiotics tested (all zones ≥ 52mm in diameter), thus establishing that the annotated β-lactamase genes did not confer resistance to the β-lactam antibiotics in the strains tested. Additionally, the β-lactamase
### Table 4. *Bifidobacterium* derived aminoglycoside resistance proteins.

| *Bifidobacterium* strain | Accession number* | Gene name | Assigned as | Pfam |
|--------------------------|-------------------|-----------|-------------|------|
| *B. longum* D010A        | YP_00195405.3^a   | BLD_0109  | AG phosphotransferase | Proteins containing a protein kinase family domain, c109925 |
|                          | ZP_00121257.2^a   | Blon_03001154 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 |
|                          | ZP_00121797.2^a   | BLD_1766  | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 |
| *B. longum* BBMN68       | YP_003999751.1^a  | BBMN68_137 | AG phosphotransferases | Proteins containing a protein kinase family domain, c109925 |
|                          | YP_004001272.1^b  | BBMN_1674 | Homoserine kinase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| *B. longum* subsp. infantis CCUG 52486 | ZP_04663835.1^a  | BLIG_01916 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 |
| *B. longum* NCC 2705     | NP695320.1^a      | BL_0091   | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 |
|                          | NP696793.1^b      | BL_1642   | Desulfatase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| *B. longum* KACC 91563   | YP_005586893.1^a  | BLNIA5_00852 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 |
| *B. adolescentis* L2-32 | ZP_02028383.1^i   | BIFADO_02300 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 |
| *B. longum* subsp. infantis ATCC 55813 | ZP_03976875.1^a  | HMPREF0175_1250 | AG phosphotransferase | Proteins containing a protein kinase family domain, c109925 |
| *B. longum* subsp. infantis ATCC 15697 | YP_002322254.1^a | Blon_0773 | AG phosphotransferase | Proteins containing a protein kinase family domain, c109925 |
|                          | YP_002323612.1^a | Blon_2173 | AG phosphotransferase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| *B. longum* subsp. *longum* JDM301 | YP_003661654.1^a | BLJ_1379 | AG phosphotransferases | Proteins containing a protein kinase family domain, c109925 |
| *B. breve* UCC2003       | ABE95342.1^c      | Bbr_0651  | Conserved Hypothetical secreted protein | Homozygote surface protein 1 (MSP1) C-terminus of the PF 07462 and proteins containing a protein kinase family domain, c109925 |
|                          | ABE96255.1^d      | Bbr_1586  | AG phosphotransferases | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| *B. breve* DSM 20213     | ZP_06595772.1^c   | BIFBRE_03589 | Conserved hypothetical protein | Proteins containing a protein kinase family domain, c109925 |
|                          | ZP_06596651.1^d   | BIFBRE_04498 | Mucin desulfating sulfatase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| *B. breve* CECT 7263     | EHS85254.1^d      | CECT7263_14691 | Mucin desulfating sulfatase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
|                          | EHS85519.1^c      | CECT7263_10981 | Hypothetical protein | Homozygote surface protein 1 (MSP1) C-terminus of the PF 07462 and proteins containing a protein kinase family domain, c109925 |
| *B. breve* ACS 071 VSch 8b | YP_005583039.1^c | HMPREF9228_1217 | Phosphotransferase enzyme domain protein | Homozygote surface protein 1 (MSP1) C-terminus of the PF 07462 and proteins containing a protein kinase family domain, c109925 |
|                          | YP_005583418.1^d | HMPREF9228_1637 | Putative mucin-desulfating sulfatase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| *B. animalis* subsp. lactis Bb12 | YP_005575653.1^e | BIF_00526 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
|                          | YP_005576071.1^f | BIF_01665 | AG 3’ phosphotransferase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| *B. dentium* ATCC 27678  | ZP_02918244.1^g   | BIFDEN_01548 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| *B. dentium* Bd1         | YP_003361041.1^h  | BDP_1625  | AG phosphotransferase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase enzyme family of the PF 01636 |
| *B. dentium* ATCC 27679  | ZP_07455726.1^i   | HMPREF0168_0285 | Conserved hypothetical protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase enzyme family of the PF 01636 |
Table 4 (continued).

| Bifidobacterium strain | Accession number | Gene name | Assigned as | Pfam |
|------------------------|-----------------|-----------|-------------|------|
| B. dentium JCVH/PO22   | ZP_07692628.1    | HMPREF9003_0562 | Conserved hypothetical protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase enzyme family of the PF 01636 |
| B. catenulatum DSM 16992 | ZP_0332625.1   | BIFCAT_00394 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| B. pseudocatenulatum DSM 20435 | ZP_03742521.1 | BIFPSEUDO_03094 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| B. adolescentis ATCC 15703 | YP_910027.1 | BAD_1164 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| B. bifidum S17         | YP_003938274.1  | BBIF_0495 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
|                        | YP_003938776.1  | BBIF_0997 | Mucin de-sulfatase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
|                        | YP_00399526.1   | BBIF_1747 | AG transferase | Phosphotransferase enzyme family of the PF 01636 and AG phosphotransferases of the aph family cd 05150 |
| B. bifidum PRL 2010    | YP_003970614.1  | BBPR_0470 | AG phosphotransferase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| B. bifidum BGN4        | YP_006393921.1  | BBB_0447 | AG phosphotransferase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
|                        | YP_006394449.1  | BBB_0978 | N-acetyl hexosamine kinase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| B. bifidum NCIMB 41171 | ZP_07801902.1   | BBNG_00382 | Conserved hypothetical protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| B. angulatum DSM 20098  | ZP_04447474.1   | BIFANG_02451 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 |
| B. animalis subsp. lactis HN019 | YP_002469703.1 | BLA_0835 | AG phosphotransferase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
|                        | ZP_02963373.1   | BIFLAC_04950 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| B. animalis subsp. animalis ATCC 25527 | YP_006280402.1 | BANAN_06155 | AG phosphotransferase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
|                        | YP_006279244.1  | BANAN_00270 | AG phosphotransferase | Phosphotransferase family with PF 01636 and aminoglycoside phosphotransferases of the aph family cd 05150 |
| B. longum subsp. longum JCM1217 | YP_004221381.1  | BLLJ_1622 | AG phosphotransferase | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| Bifidobacterium sp. 12.1_47BFAA | ZP_07941182.1 | HMPREF0177_00575 | Phosphotransferase enzyme family protein | Proteins containing a protein kinase family domain, c109925 and phosphotransferase family with PF 01636 |
| B. longum subsp. infantis 157F | YP_004209317.1 | BLIF_1400 | Hypothetical protein | Proteins containing a protein kinase family domain, c109925 |

* Same superscript indicates proteins share >90% sequence percentage identity.

AG: aminoglycoside

doi: 10.1371/journal.pone.0082653.t004

nitrocefin tests also demonstrated a lack of β-lactamase activity among the bifidobacteria strains tested. In contrast, when these strains were tested using aminoglycoside antibiotic discs, each of the strains were shown to be highly resistant to each of the antibiotics, i.e. zone of inhibition was small or absent (Table 5).

**Disruption of the Bbr_0651 and Bbr_1586 genes of B. breve UCC2003**

An insertional inactivation approach was implemented to determine to what extent putative aminoglycoside resistance genes contribute to the observed aminoglycoside resistance in bifidobacteria. B. breve UCC2003 was selected as a target, due to the success with which gene disruptions have been previously created in this strain [50,51]. The genes Bbr_0651 and Bbr_1586 were targeted for disruption. The gene Bbr_0651 encodes a putative conserved hypothetical secreted protein which shares 99% identity with other putative phosphotransferase enzymes (e.g. BIFBRE_03589 from B. breve DSM 20213) and also shares 71% identity with an aminoglycoside phosphotransferase from B. longum subsp. longum ATCC 55813 (HMPREF0175_1250). The gene Bbr_1586 encodes a putative phosphotransferase family enzyme, which also shares 91% identity with a putative aminoglycoside phosphotransferase from B. longum subsp. longum ATCC 55813 (HMPREF0175_1250).
Additionally, MICs were performed to compare aminoglycoside resistance of the mutants and the wild-type, suggesting reduced aminoglycoside resistance in the mutants as compared to the wild-type (Table 6). These results thereby demonstrate that both Bbr_0651 and Bbr_1586 contribute to aminoglycoside resistance and can be assigned as aminoglycoside resistance determinants. To verify that the observed changes to phenotype were as a direct result of disruption to the genes Bbr_0651 and Bbr_1586, rather than as an indirect consequence of the mutagenesis strategy, MICs were conducted on another insertion mutant created in B. breve UCC2003, namely B. breve UCC2003-gosG [51]. This mutant was created previously using the same protocol that was used to create the mutants Bbr_0651 and Bbr_1586, but in this instance the Bbr_0529 (gosG) gene is disrupted. The antibiotic resistance phenotype of this mutant was similar to that of the wild-type B. breve UCC2003 (Table 6).

To further confirm that the observed reduction in aminoglycoside resistance of the insertion mutant was as a direct result of disruption to the putative AG resistance proteins, complementation studies were performed with one of the mutants. The MIC results demonstrate that following complementation, the resistance of the insertion mutant was restored to levels almost identical to those of the wild-type B. breve UCC2003 (Table 5). Additionally, MICs were performed to compare aminoglycoside resistance of the wild-type to that of the two insertion mutants. As shown in Table 6, after 24 hours incubation, the insertion mutants were more sensitive to gentamycin, streptomycin and neomycin, while the introduction of Bbr_1586 also increased resistance to neomycin by 2-fold, relative to the control E. coli XL1-blue-pBC1.2 strain (Table 6).

**Table 5. Antibiotic resistance of bifidobacteria strains as assessed through antibiotic disc assays.**

| Antibiotic (microgram/per disc) | β-lactams | Aminoglycosides |
|-------------------------------|-----------|-----------------|
| Bifidobacteria species        | PEN 10    | AMP 25IU |
| B. breve DSM 20213            | 7mm       | 65mm |
| B. animalis subsp. lactis Bb12| 65mm      | 55mm |
| B. pseudocalterulatum DSM 20438| 61mm     | 56mm |
| B. gallicum DSM 20093          | 60mm      | 59mm |
| B. angulatum DSM 20098         | 64mm      | 65mm |
| B. breve UCC2003               | 67mm      | 56mm |
| B. breve UCC2003-0651-tet      | 52mm      | 57mm |
| B. breve UCC2003-1586-tet      | 62mm      | 57mm |
| B. breve UCC2003-1586-tet-pBC1.2-Bbr_1586 | 62mm | 59mm |
| AMP, ampicillin; PEN, penicillin; KAN, kanamycin; GEN, gentamycin; STR, streptomycin; NEO, neomycin |
| Values are average of triplicate plate results (SD±1mm for all samples, on all antibiotics) |
| doi: 10.1371/journal.pone.0082653.t005 |

**Table 6. MIC values (mg/L) of wild-type B. breve UCC2003 compared to mutants as determined by broth micro-dilution assay (MRS+cysteine for Bifidobacterium and LB broth for E. coli cultures).**

| Sample                          | GEN | NEO | STR | KAN |
|---------------------------------|-----|-----|-----|-----|
| B. breve UCC2003 wild-type      | >1024 | >1024 | 1024 | 2-4096 |
| B. breve UCC2003-0651-tet       | 256  | >1024 | 1024 | >4096 |
| B. breve UCC2003-1586-tet       | 256  | >1024 | 1024 | >4096 |
| B. breve UCC2003-gosG           | >1024 | >1024 | 1024 | >4096 |
| B. breve UCC2003-1586-tet-pBC1.2-Bbr_1586 | >1024 | 1024 | 256 | 4096 |
| B. breve UCC2003 wild-type*     | 4096 | 4096 | 1024 | 4096 |
| B. breve UCC2003-pBC1.2_Bbr_1586| 4096 | 4096 | 2048 | 8192 |
| B. breve UCC2003-pBC1.2_Bbr_0651| 4096 | 4096 | 1024 | 4096 |
| B. breve UCC2003-pBC1.2_Bbr_0651+0650 | 4096 | 4096 | 1024 | 4096 |
| E. coli XL1-blue-pBC1.2         | <1   | 4   | <2  | <2  |
| E. coli XL1-blue-pBC1.2_Bbr_0651+0650 | 2   | 8   | <2  | <2  |
| E. coli XL1-blue-pBC1.2_Bbr_0651 | 2   | 8   | <2  | <2  |
| E. coli XL1-blue-pBC1.2_Bbr_1586 | <1   | 8   | <2  | <2  |
| GEN, gentamycin; NEO, neomycin; STR, streptomycin; KAN, kanamycin |
| Values based on triplicate readings, which were identical in all cases |
| * Higher ranges of antibiotics used to test effect of additional gene copies on MICs compared to wild-type (High range used: 256-16384mg/L for Gent/Neo; 1024-65536mg/L for Strep/Kan) |
| doi: 10.1371/journal.pone.0082653.t006 |
Discussion

The human microbiota contributes to numerous vital gut functions including nutrient metabolism, vitamin biosynthesis and immune system development [52]. However, it has more recently been postulated that this complex microbial population is also a sizeable reservoir for antibiotic resistance genes [53,54], and that microbes containing such genes can become dominant in the human gastrointestinal tract following antibiotic exposure [36,55,56]. There is also a risk that such genes could be transferred to other microbes, including those passing through the gastrointestinal tract, and thus could contribute to the dissemination of antibiotic resistance genes [53]. Commensal bifidobacteria have received significant attention as a consequence of frequent reports of the beneficial impact of particular species or strains on health [25,57,58], with only one species, *B. dentium*, being a known human (cariogenic) pathogen [59]. Furthermore, given the frequent use of *Bifidobacterium* strains as probiotics, any association between these microbes and potentially transferrable antibiotic resistance would be a cause for concern.

Several studies have utilised culture-based approaches to determine the resistance or sensitivity of bifidobacteria to various families of antibiotics, though the genetics underlying this resistance has not been examined extensively [29,31,35,43]. The exceptional studies that exist have focused on mutations to genes encoding specific targets and the resulting increased antibiotic resistance. In one instance the genetic basis for the enhanced resistance of mutants of *B. bifidum* Yakult strain YIT4007 was investigated [32]. Briefly, YIT 4007 was isolated from the progenitor strain YIT 4001 by screening mutants of YIT 4001 for enhanced resistance to neomycin, erythromycin and streptomycin. To investigate the potential transfer of resistance, genetic tests on the mutants were also performed. The study identified several chromosomal mutations, namely mutations on 3 copies of the 23S ribosomal RNA genes, an 8bp deletion of the *rulD* gene and a mutation on the *rpsL* gene, which they considered to be responsible for the observed increased resistance to aminoglycoside antibiotics, at levels at which the progenitor strain was sensitive. As these mutations were not located on mobile genetic elements, it was concluded that this strain posed no risk of antibiotic resistance transfer. Another study investigated antibiotic resistance levels in 26 *B. breve* strains and found that a Yakult probiotic strain demonstrated atypically high resistance to streptomycin [37]. Genetic analysis determined that a mutation to the *rpsL* gene, which encodes the ribosomal protein S12, was responsible. In light of the general rarity of studies investigating the genetic basis for innate aminoglycoside resistance in bifidobacteria, this study examined the contribution of in *silico* assigned aminoglycoside resistance proteins to the resistance phenotype of bifidobacteria. Indeed, to our knowledge, ours is the first study that utilises a targeted in *silico* based approach to assess the existence and prevalence of putative β-lactamase and aminoglycoside resistance proteins in the *Bifidobacterium* genus and to subsequently investigate if representative genes confer a resistant phenotype.

With respect to the putative β-lactamases, it was noted that several proteins of potential relevance have been assigned across the *Bifidobacterium* genus. However, none of these were clear representatives of any of the Ambler classes of β-lactamases. When all of the sequences were considered it appeared they could be grouped broadly into one of three groups, i.e. those which were members of Pfam 00144, those of Pfam 07521 or Pfam 12706. Most frequently these sequences were annotated as hypothetical proteins, while others were annotated as β-lactamases. To detect such a high prevalence of putative β-lactamases amongst bifidobacteria was surprising given that previous laboratory based investigations have shown bifidobacteria to be sensitive to commonly prescribed β-lactams [29,31,35,43,60]. Indeed, for example, in 2010 Xiao et al. demonstrated that 23 investigated bifidobacterial strains were sensitive to all β-lactams tested [31]. In order to examine whether these annotated β-lactamase sequences resulted in a resistance phenotype, we selected a representative number of bifidobacteria strains, which had been identified in the *in silico* screen as containing putative β-lactamases, and studied these further. Using a culture-based approach, the results indicated that none of the representative bifidobacterial strains which were tested were resistant to the β-lactam antibiotics. These results draw into question the significance of the high frequency of putative β-lactamases or hypothetical proteins closely related to β-lactamases in bifidobacteria genomes. The fact that the tested bifidobacteria were sensitive to β-lactam antibiotics and showed no β-lactamase activity (as assessed using the nitrocefin test), despite the presence of annotated β-lactams in their genome, as well as the lack of sequence homology when compared to known β-lactamase sequences, led us to conclude that this is most likely due to significant mis-annotation of protein sequences across publically available *Bifidobacterium* genomes. Alternatively, it could be proposed that these β-lactamase genes are repressed in bifidobacteria. While this possibility could be assessed by expression-based studies, which may be investigated in future studies, we think it more likely that the mis-annotation of these putative resistance genes is the basis for the absence of resistance. Indeed, there are previous examples of the mis-assignment of genes as penicillin resistance genes, such as the mis-annotation of the bile salt hydrolase genes as penicillin acylases [61,62]. With the development of high-throughput genome sequencing methods, automated approaches to annotation became increasingly popular [63]. However, this study provides an example of how mis-annotation of the first bifidobacteria genomes has led to further mis-annotation of subsequent genome sequences. Notably, several studies have investigated the extent of mis-annotation of genomes and noted the frequency of this issue [64-67], with one study finding an 8% error rate across just 340 genes [65]. Such an approach, which is likely to continue as sequencing becomes even more efficient and cost effective, and is coupled to automated annotation, could cause undue concern about the safety of a species, for example, in the case where antibiotic resistance protein sequences are detected in a potential probiotic bacterium. Thus, our results highlight the necessity for...
laboratory-based investigations into the function of annotated proteins.

Various culture-based studies have demonstrated that bifidobacteria are resistant to the aminoglycoside family of antibiotics [29,31,35]. This phenomenon was also apparent in the representative strains employed for this study. This resistance has been suggested to be due to the absence of appropriate cytochrome-mediated transport systems in bifidobacteria for aminoglycoside uptake [68]. This theory was first proposed in 1979, when it was demonstrated that Bacteroides fragilis and Clostridium perfringens were resistant to aminoglycoside antibiotics due to an inability to synthesize cytochrome structures and thus cannot utilise electron transport mediated transfer that is proposed to facilitate the entry of aminoglycosides into the cells [68]. It has since been accepted that bifidobacteria are intrinsically resistant to aminoglycoside antibiotics by the same mechanism [69]. However, we hypothesized that the resistance proteins detected in our in silico screen could be providing additional resistance beyond this intrinsic resistance and thus could contribute to the survival of bifidobacteria at higher concentrations of aminoglycosides.

The in silico screen highlighted the prevalence of putative aminoglycoside resistance proteins across members of the Bifidobacterium genus. Though a high frequency of aminoglycoside resistance proteins and related hypothetical proteins were detected, the sequences could be broadly categorised as those which were members of the Pfam 01636, those containing a protein kinase family domain c109925 and those which belonged to the Pfam 01636 and contained the domain c109925. To investigate the hypothesis that these putative resistance proteins contribute to aminoglycoside resistance in bifidobacteria, putative aminoglycoside resistance genes from one strain were mutated. More specifically, using B. breve UCC2003 as a representative strain, we disrupted the 2 genes present in this strain, which were detected in the in silico screen as being the genes potentially encoding aminoglycoside resistance proteins. Following confirmation that successful homologous recombination had occurred (at the targeted gene specific sites) within B. breve UCC2003, aminoglycoside resistance of the respective mutants was tested. These experiments demonstrated that disruption of either of these 2 aminoglycoside resistance genes impacted on the resistance phenotype of B. breve UCC2003 (Table 5). Thus, we propose that while the lack of cytochrome-mediated transport of the aminoglycosides into the cells may be an important contributor to the observed resistance phenotype among bifidobacteria and alone are sufficient to result in the strains being considered to be clinically resistant, these annotated aminoglycoside resistance proteins are true aminoglycoside resistance proteins, which further enhance this intrinsic resistance. To investigate this hypothesis further, MICs were conducted to compare the resistance of the mutants compared to the wild-type at higher levels of aminoglycoside antibiotics. The results established that the mutants exhibited greater sensitivities to gentamycin, streptomycin and kanamycin compared to the wild-type strain (Table 6).

Unfortunately, the strategy employed precluded the creation of a double mutant that lacks both Bbr_1586 and Bbr_0651. Should methods be developed to create deletion mutants in Bifidobacterium in the future, such a mutant can be created in order to determine if the inactivation of both aminoglycoside resistance genes results in a more pronounced aminoglycoside sensitive phenotype. Through complementation studies, it was demonstrated that reintroduction of the Bbr_1586 gene restored resistance to gentamycin and kanamycin to levels which were essentially identical to those of the wild-type (Table 6). Additionally, when an extra, plasmid-borne copy of the gene Bbr_1586 was added to wild-type B. breve UCC2003, a 2-fold increased resistance was seen for streptomycin and kanamycin. However, additional copies of Bbr_1586 did not enhance resistance of the wild-type B. breve UCC2003 to neomycin and gentamycin. This may be due to the fact that the resistance of the wild-type to these antibiotics was already high (Table 6), and thus the aminoglycoside resistance proteins may have been saturated or unable to provide additional resistance to such high levels of antibiotics. Moreover, when an additional copy of either Bbr_0651 or Bbr_0650 was added to the wild-type B. breve UCC2003, no additional enhanced resistance occurred for any of the aminoglycosides tested. This suggests that the genome-encoded copy of this gene is already performing its function optimally. The results in relation to Bbr_1586 and streptomycin resistance are puzzling in that, while disruption to the putative aminoglycoside resistance genes resulted in a reduction in streptomycin resistance and additional plasmid-encoded copies of these genes increased the resistance to streptomycin compared to wild-type levels, complementation failed to restore streptomycin levels to those seen in the wild-type. One possible explanation is that there are additional genes downstream of Bbr_1586, which contribute to streptomycin resistance and are impacted upon in a polar manner following mutagenesis by plasmid insertion. The role of Bbr_0651 and Bbr_1586 as aminoglycoside resistance determinants was further confirmed through the provision of enhanced protection against at least one aminoglycoside upon their expression in E. coli XL1-blue.

Ultimately, it is evident that both Bbr_0651 and Bbr_1586 contribute to aminoglycoside resistance in B. breve UCC2003. Importantly however, given that these resistance genes are not located on or near mobile genetic elements, they are unlikely to pose a risk of transferring antibiotic resistance to other bacteria populations. In fact it may be beneficial for species of Bifidobacterium to possess such non-transferable aminoglycoside resistance genes. Such species would survive higher levels of aminoglycosides than species without this additional genetic resistance, and so they may be more suitable as potential probiotics for use during aminoglycoside therapy. The results of this study re-emphasise the fact that annotation of genomes is a predictive process and that the results generated must be interpreted cautiously. Nonetheless, this approach did accurately predict the presence of aminoglycoside resistance proteins in bifidobacterial genomes. Crucially, laboratory based experiments were carried out to validate these annotations and similar such laboratory experiments are required to assess other putative antibiotic resistance genes in bifidobacteria and other genera.
Supporting Information

Table S1. Primers used in this study. (PDF)

References

1. Fleming A (1979) On the antibacterial action of cultures of a penicillin, with special reference to their use in the isolation of B. influenzae. British Journal of Experimental Pathology 60: 3-15.

2. Davies J, Davies G (2007) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 71: 417-433. doi:10.1128/MMBR.00116-10. PubMed: 20805405.

3. Bush K (2012) Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol 12: 527-534. doi:10.1016/j.coph.2012.06.003. PubMed: 22748801.

4. Walsh C (2000) Molecular mechanisms that confer antibiotic drug resistance. Nature 406: 775-781. doi:10.1038/35021219. PubMed: 10963607.

5. Mingeot-Leclercq MP, Glupczynski Y, Tuikens PM (1999) Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43: 727-737. PubMed: 10103173.

6. Jacoby G, Gorini L (1987) The effect of streptomyein and other aminoglycoside antibiotics on protein synthesis. Mechanism of Action: Springer pp. 726-747.

7. Davies J, Wright GD (1997) Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 5: 234-240. doi:10.1016/S0968-844X(97)01033-0. PubMed: 9211644.

8. Shaw KJ, Rather PN, Hare RS, Miller GH (1993) Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57: 138-163. PubMed: 8352652.

9. Kotra LP, Mobashery S (1998) β-Lactam antibiotics, β-lactamases and bacterial resistance. Bulletin de l'Institut Pasteur 96: 139-150. doi:10.1016/S0001-6096(98)80209-2.

10. Page MGP (2012) Beta-Lactam Antibiotics. Antibiotic Discovery and Development: 79-117. doi:10.1007/978-1-4614-1400-1_3.

11. Tipper D (1979) Mode of action of β-lactam antibiotics. Reviews of Infectious Diseases 1: 39-53. doi:10.1093/clinids/1.1.39.

12. Tipper DJ, St roominger JL (1965) Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-ala-nyl-D-alanine. Proc Natl Acad Sci U S A 54: 1133-1144. doi:10.1073/pnas.54.11.1133. PubMed: 5219821.

13. Georgopapadakou NH (1993) Penicillin-binding proteins and bacterial resistance to beta-lactams. Antimicrob Agents Chemother 37: 2045-2053. doi:10.1128/AAC.37.10.2045. PubMed: 8257121.

14. Pitout JD, Sanders CC, Sanders WE Jr (1997) Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 103: 51-59. doi:10.1016/S0002-9347(97)00044-2. PubMed: 9236486.

15. Abraham E, Chain E (1940) An enzyme from bacteria able to destroy penicillin. Nature 45: 417-418. doi:10.1038/1493707a0.

16. Richmond MH, Sykes RB (1973) The β-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol 9: 31-88. doi:10.1016/S0065-2911(08)60376-8. PubMed: 4581138.

17. Ambler R (1980) The Structure of beta-lactamases. Philosophical Transactions of the Royal Society of London B, Biological Sciences 289: 321-331. doi:10.1098/rstb.1980.0049.

18. Bush K (1989) Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'. Antimicrob Agents Chemother 33: 264-270. doi:10.1128/AAC.33.2.264. PubMed: 2658780.

19. Bush K, Jacoby GA (2010) Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54: 969-976. doi:10.1128/AAC.01009-09. PubMed: 19995920.

20. Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39: 1211-1233. doi:10.1128/AAC.39.6.1211. PubMed: 7574506.

21. Commission E (2008) Technical guidance prepared by the Panel on Additives and Products or Substances used in; Feed Animal Feed (FEEDAP) on the update of the criteria used in the assessment of bacterial resistance to antibiotics of human or veterinary importance. EFSA J. 1:1-15

Author Contributions

Conceived and designed the experiments: FF PDC RPR CS GFF MOCM DVs. Performed the experiments: FF MOCM. Analyzed the data: FF PDC. Contributed reagents/materials/analysis tools: FF MOCM DVs PDC. Wrote the manuscript: FF MOCM GFF RPR CS DVs PDC.
Antibiotic Resistance in Bifidobacterium

animals and probiotic products. J Antimicrob Chemother 58: 85-94. doi: 10.1093/jac/dkt017. PubMed: 16968474.

39. Andrews JM (2009) BSAC standardized disc susceptibility testing method (version 8). J Antimicrob Chemother 64: 454-489. doi: 10.1093/jac/dkp244. PubMed: 19587067.

40. Andrews JM (2001) The development of the BSAC standardized method of disc diffusion testing. J Antimicrob Chemother 48: 29-42. doi: 10.1093/jac/48.suppl_1.29. PubMed: 11420335.

41. Andrews JM (2001) BSAC standardized disc susceptibility testing method. J Antimicrob Chemother 48: 43-57. doi: 10.1093/jac/48.suppl_1.43. PubMed: 11420336.

42. Andrews JM (2001) Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48: 5-16. doi: 10.1093/jac/dkl197. PubMed: 11420334.

43. Moubarak C, Cavini F, Vaugien L, Butel MJ, Doucet-Populaire F (2005) Antimicrobial susceptibility of bifidobacteria. J Antimicrob Chemother 55: 38-44. PubMed: 15574479.

44. Lee DT, Rosenblatt JE (1983) A comparison of four methods for detecting β-lactamase in anaerobic bacteria. Diagn Microbiol Infect Dis 1: 173-175. doi: 10.1016/0732-8893(83)90048-2. PubMed: 6370561.

45. O'Connor Motherway M, O'Driscoll J, Fitzgerald GF, Van Sinderen D (2009) Overcoming the restriction barrier to plasmid transformation and targeted mutagenesis in Bifidobacterium breve UCC2003. Microbiol Biotechnol 2: 321-332. doi: 10.1111/j.1751-7915.2008.00071.x. PubMed: 21261927.

46. Mazzé A, O'Connor-Motherway M, Fitzgerald GF, Deutscher J, van Sinderen D (2007) Identification and characterization of a fructose phosphotransferase system in Bifidobacterium breve UCC2003. Appl Environ Microbiol 73: 545-553. doi: 10.1128/AEM.01496-06. PubMed: 17089814.

47. Lambert P, O'Connor-Motherway M, van Sinderen D, Mayo B (2007) Functional analysis of the pbc1 replicon from Bifidobacterium catenulatum L48. Appl Microbiol Biotechnol 76: 1395-1402. doi: 10.1007/s00253-007-1115-5. PubMed: 17704917.

48. de Vos WM, Kleerebezem M, O'Connell-Motherway M, O'Driscoll J, Fitzgerald GF, Van Sinderen D (2008) A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes. J Bacteriol 177: 7011-7018. PubMed: 1852504.

49. de Vos WM, Moutarek C, Gavini F, Vaugien L, Butel MJ, Doucet-Populaire F (2008) Antibiotic resistance reservoir in the human microbiota: relationship to diet, obesity and time in mouse models. Gut 59: 1635-1642. doi: 10.1136/gut.2010.215665. PubMed: 2026643.

50. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG et al. (2007) Selective increases of bifidobacteria in gut microbiota improve high-fat diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50: 2374-2383. doi: 10.1007/s00122-007-0791-0. PubMed: 17823788.

51. Mitsuoka T (1990) Bifidobacteria and their role in human health. Journal of Industrial Microbiology 6: 263-267. doi: 10.1007/BF01578787.

52. Ventura M, Turnoni F, Zomer A, Foroni E, Giubellini V et al. (2009) The Bifidobacterium dentium Bd1 genome sequence reflects its genetic adaptation to the human oral cavity. PLoS Genet 5: e1000785. doi:10.1016/j.tim.2004.07.004. PubMed: 15337162.

53. Andrews JM (2001) Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48: 5-16. doi: 10.1093/jac/dkl197. PubMed: 11420334.

54. Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR (2008) Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A 105: 13580-13585. doi: 10.1073/pnas.080437105. PubMed: 18757757.

55. Andrews JM (2001) BSAC standardized disc susceptibility testing method. J Antimicrob Chemother 48: 43-57. doi: 10.1093/jac/48.suppl_1.43. PubMed: 11420336.

56. Andrews JM (2001) Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48: 5-16. doi: 10.1093/jac/dkl197. PubMed: 11420334.

57. Lambert P, O'Connor-Motherway M, van Sinderen D, Mayo B (2007) Functional analysis of the pbc1 replicon from Bifidobacterium catenulatum L48. Appl Microbiol Biotechnol 76: 1395-1402. doi: 10.1007/s00253-007-1115-5. PubMed: 17704917.

58. de Vos WM, Kleerebezem M, O'Connell-Motherway M, O'Driscoll J, Fitzgerald GF, Van Sinderen D (2008) A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes. J Bacteriol 177: 7011-7018. PubMed: 1852504.

59. de Vos WM, Moutarek C, Gavini F, Vaugien L, Butel MJ, Doucet-Populaire F (2008) Antibiotic resistance reservoir in the human microbiota: relationship to diet, obesity and time in mouse models. Gut 59: 1635-1642. doi: 10.1136/gut.2010.215665. PubMed: 2026643.

60. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG et al. (2007) Selective increases of bifidobacteria in gut microbiota improve high-fat diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50: 2374-2383. doi: 10.1007/s00122-007-0791-0. PubMed: 17823788.

61. Mitsuoka T (1990) Bifidobacteria and their role in human health. Journal of Industrial Microbiology 6: 263-267. doi: 10.1007/BF01578787.

62. Ventura M, Turnoni F, Zomer A, Foroni E, Giubellini V et al. (2009) The Bifidobacterium dentium Bd1 genome sequence reflects its genetic adaptation to the human oral cavity. PLoS Genet 5: e1000785. doi:10.1016/j.tim.2004.07.004. PubMed: 15337162.